An observational study in Obesity, Metabolic Abnormalities and Health, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 575 studies in Obesity with a site in Canada — 102 open to participants now, 151 under way, 47 of them phase 3. Obesity · Canada.
Among the 575 studies in Obesity with a site in Canada, this one has the largest planned enrollment of the 91 observational ones that give a count, is one of 54 that started in 2026, is one of 91 observational ones, reaches primary completion later than 149 of the 150 other live ones, and was the 540th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →102 of the 575 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+ · Women only
McMaster University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
575 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 63 · Phase 3 98 · Phase 4 26
First in 1997; this study’s year is marked. 54 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 74 across the 480 interventional studies, 52 across the 91 observational. Of the 362 that completed or were terminated, 49 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 575 have an industry lead sponsor. The 10 most frequent:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval is the lead sponsor of 15 studies on the registry; 9 are open to participants now.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
46 of the studies in Obesity with a site in Canada that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 575 studies in Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.
A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.
This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:
Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.
To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:
Meet at least one of the following five criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval
Other: Behavioral and Pharmacological Treatments
Behavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs.
Success or failure of obesity medicine interventions
1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m\^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis 2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available) 3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts 4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts 5. Mental Health Parameters: As recorded in medical charts
Time frame: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2051, 300 months later.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 300 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval